Our analysis revealed a significant increase in overall survival (OS) among patients with high EGLN2 mRNA levels in tumor tissues (p = 0.0052) (Figure 4), alongside those with low levels of EGLN3 (p = 0.0272) (Figure 4). The gene discussed is EGLN2; the disease is neoplasm.